Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 21:11:478.
doi: 10.3389/fphar.2020.00478. eCollection 2020.

Traditional Chinese Medicine Combined With Chemotherapy and Cetuximab or Bevacizumab for Metastatic Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Ningning Liu  1   2 , Chaojun Wu  1   2 , Ru Jia  1   2 , Guoxiang Cai  3 , Yan Wang  1 , Lihong Zhou  1 , Qing Ji  1 , Hua Sui  1 , Puhua Zeng  4 , Haijuan Xiao  5 , Huaimin Liu  6 , Jiege Huo  7 , Yuanyuan Feng  1 , Wanli Deng  1 , Qi Li  1   2
Affiliations

Traditional Chinese Medicine Combined With Chemotherapy and Cetuximab or Bevacizumab for Metastatic Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Ningning Liu et al. Front Pharmacol. .

Abstract

Background: Huangci Granule is a traditional Chinese medicine for treating metastatic colorectal cancer (mCRC).

Objective: To evaluate the efficacy and safety of Huangci Granule combination with chemotherapy and cetuximab (CET) or bevacizumab (BV) for treating mCRC.

Methods: We performed a randomized, controlled, and double-blind trial and recruited patients with mCRC who were planned to undergo chemotherapy combined with CET or BV. The treatment group was treated with Huangci Granule, while the control group was treated with placebo. Continuous treatment until disease progression, death, intolerable toxicity or up to 6 months. The primary endpoint was progression-free survival (PFS), and the secondary endpoint was quality of life and safety.

Result: 320 patients were randomly assigned to receive treatment, including 200 first-line patients and 120 second-line patients. In the first-line treatment, the median PFS was 9.59 months (95% CI, 6.94-13.25) vs 6.89 months (95% CI, 4.99-9.52) in treatment group and control group (HR, 0.69; 95% CI, 0.50-0.97; P = 0.027). Chinese medicine was an independent factor affecting the PFS. In the second-line treatment, the median PFS was 6.51 months (95% CI, 4.49-9.44) vs 4.53 months (95% CI, 3.12-6.57) in the treatment group and control group (HR, 0.65; 95% CI, 0.45-0.95; P = 0.020). Compared with the control group, "role function," "social function," "fatigue," and "appetite loss" were significantly improved in the treatment (P < 0.05) and drug related grades 3 to 4 adverse events were less.

Conclusion: Huangci Granule combined with chemotherapy and CET or BV can prolong the PFS of mCRC, improve the quality of life, reduce adverse reactions, and have good safety.

Keywords: cetuximab (CET) or bevacizumab (BV); metastatic colorectal cancer; progression-free survival; quality of life; traditional Chinese medicine.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Trial profile.
Figure 2
Figure 2
Kaplan-Meier survival estimates for progression-free survival. (A) first-line. (B) second-line.
Figure 3
Figure 3
(A) Cox and subgroup analysis for PFS Univariate Cox proportional hazards regression analysis of PFS (B) Subgroup analysis for PFS.
Figure 4
Figure 4
Quality of life scores between the two groups. *P < 0.05. (A) Functional scales. (B) Symptom scales.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bennouna J., Sastre J., Arnold D., Österlund P., Greil R., Cutsem E. V., et al. (2013). Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 14 (1), 29–37. 10.1016/S1470-2045(12)70477-1 - DOI - PubMed
    1. Bray F., Ferlay J., Soerjomataram I., Siegel R., Torre L.A, Jemal A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68 (6), 394–424. 10.3322/caac.21492 - DOI - PubMed
    1. Chen W., He J., Sun K., Zhang R., Zhang H., Zhang S., et al. (2018). Cancer incidence and mortality in China 2014. Chin. J. Cancer Res. 1 (30), 1–12. 10.21147/j.issn.1000-9604.2018.01.01 - DOI - PMC - PubMed
    1. Conroy T., Bleiberg H., Glimelius B. (2003). Quality of life in patients with advanced colorectal cancer: what has been learnt? Eur. J. Cancer 39 (3), 287–294. 10.1016/s0959-8049(02)00664-0 - DOI - PubMed
    1. Cunningham D., Humblet Y., Siena S., Khayat D., Blieberg H., Santoro A., et al. (2004). Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New Engl. J. Med. 351 (4), 337–345. 10.1056/NEJMoa033025 - DOI - PubMed

LinkOut - more resources